<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-88058" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lumateperone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cooper</surname>
            <given-names>Dylan</given-names>
          </name>
          <aff>Rutgers School of Dental Medical School, Newark, NJ</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dylan Cooper declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-88058.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Lumateperone is a medication used to manage and treat schizophrenia and other neuropsychiatric disorders. It is a second-generation atypical antipsychotic medication that exhibits a novel mechanism of action. Lumateperone's mechanism of action involves simultaneous modulation of dopaminergic, serotonergic, and glutamatergic neurotransmission. This activity describes the indications, mechanism of action, and administration of lumateperone as a valuable treatment of schizophrenia. This activity will highlight the mechanism of action, adverse effect profile, and other key factors such as dosage and interactions for the interdisciplinary healthcare team responsible for treating individuals with schizophrenia and other neuropsychiatric disorders.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of lumateperone for the treatment of schizophrenia.</p></list-item><list-item><p>Summarize the recent findings of clinical trials involving lumateperone, a novel treatment for several neuropsychiatric disorders.</p></list-item><list-item><p>Review important clinical factors relating to the use of lumateperone for the treatment of neuropsychiatric disorders.</p></list-item><list-item><p>Outline the importance of improving care coordination amongst interprofessional team members to improve patient outcomes affected by schizophrenia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=88058&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=88058">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-88058.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Schizophrenia is a debilitating psychiatric disorder characterized by positive symptoms, such as hallucinations and delusions, and negative symptoms, such as apathy, depression, and deficits in cognitive functioning.<xref ref-type="bibr" rid="article-88058.r1">[1]</xref>&#x000a0;The introduction of second-generation antipsychotics has dramatically improved the ability of healthcare professionals to manage and treat schizophrenia and provide an increased quality of life to patients afflicted with this disease.</p>
        <p>The discovery of the role of 5HT-2A receptor antagonism in reducing the adverse motor effects caused by D2 receptor blockade has significantly improved treatment options available for those with schizophrenia. However, even with the repertoire of antipsychotics introduced in the past few decades, they have generally been more effective against positive symptoms rather than negative symptoms of schizophrenia. Additionally, they are associated with an increased incidence of adverse metabolic effects, such as weight gain and hyperprolactinemia.<xref ref-type="bibr" rid="article-88058.r2">[2]</xref>&#x000a0;As a result, an antipsychotic with decreased incidence of side effects and a broader range of efficacy against schizophrenia would provide a valuable addition to current treatments.<xref ref-type="bibr" rid="article-88058.r3">[3]</xref></p>
        <p>One such medication, lumateperone, is a recently FDA-approved antipsychotic that provides a unique mechanism of action for treating schizophrenia.<xref ref-type="bibr" rid="article-88058.r4">[4]</xref>&#x000a0;Clinical trials have found placebo-level metabolic adverse effects, a very low incidence of extrapyramidal symptoms, and potentially improved coverage of negative symptoms of schizophrenia.<xref ref-type="bibr" rid="article-88058.r2">[2]</xref><xref ref-type="bibr" rid="article-88058.r5">[5]</xref>&#x000a0;Its current indication is for managing acute schizophrenia, with clinical studies underway to determine its long-term safety and efficacy for this condition.<xref ref-type="bibr" rid="article-88058.r2">[2]</xref><xref ref-type="bibr" rid="article-88058.r6">[6]</xref></p>
        <p>In addition to its favorable side effect profile, lumateperone demonstrates a unique pharmacodynamic profile not found in other second-generation atypical antipsychotics in that it interacts with glutamatergic pathways in addition to dopaminergic and serotonergic pathways. As a result, it provides a distinctive mechanism of action to treat schizophrenia.<xref ref-type="bibr" rid="article-88058.r1">[1]</xref><xref ref-type="bibr" rid="article-88058.r7">[7]</xref></p>
        <p>Lumateperone effectiveness in treating acutely exacerbated schizophrenia has shown to be statistically significant vs. placebo in a four-week Phase II and Phase III clinical trial at 42 mg/day as well as a 6-week phase III trial.&#x000a0;</p>
        <p>There are also suggestions that patients currently stable on an antipsychotic may show symptomatic improvement when adding lumateperone as an adjunctive treatment.<xref ref-type="bibr" rid="article-88058.r5">[5]</xref><xref ref-type="bibr" rid="article-88058.r8">[8]</xref>&#x000a0;</p>
        <p>Lumateperone has been studied for bipolar depression with positive outcomes in one trial, and in the other trial, lumateperone did not separate itself from the placebo.<xref ref-type="bibr" rid="article-88058.r9">[9]</xref>&#x000a0;A trial with lumateperone for agitation in patients with dementia was terminated; researchers determined that the trial would not meet the primary endpoints.<xref ref-type="bibr" rid="article-88058.r10">[10]</xref></p>
        <p>Lumateperone is currently approved for the treatment of schizophrenia in adults. In addition, it has also been approved as either a monotherapy or an adjunctive treatment with lithium or valproate for treating bipolar depression associated with bipolar I and II disorder.<xref ref-type="bibr" rid="article-88058.r11">[11]</xref></p>
      </sec>
      <sec id="article-88058.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Lumateperone's mechanism of action involves simultaneous modulation of dopaminergic, serotonergic, and glutamatergic neurotransmission.<xref ref-type="bibr" rid="article-88058.r12">[12]</xref><xref ref-type="bibr" rid="article-88058.r5">[5]</xref>&#x000a0;Its dopaminergic actions involve pre-synaptic partial agonist and post-synaptic antagonist activity at dopamine D2 receptors.<xref ref-type="bibr" rid="article-88058.r13">[13]</xref>&#x000a0;This dual action at the dopamine D2 receptor is unique to lumateperone compared to other antipsychotics. Furthermore, It acts as a dopamine phosphoprotein modulator (DPPM).<xref ref-type="bibr" rid="article-88058.r13">[13]</xref>&#x000a0;Lumateperone is also a potent 5-HT2A receptor antagonist, with an affinity that is 60x greater than its affinity to D2 receptors.<xref ref-type="bibr" rid="article-88058.r2">[2]</xref>&#x000a0;Finally, lumateperone is the first antipsychotic to exhibit glutamatergic activity, augmenting the activity of NMDA and AMPA receptors.<xref ref-type="bibr" rid="article-88058.r3">[3]</xref><xref ref-type="bibr" rid="article-88058.r14">[14]</xref>&#x000a0;</p>
        <p>At dopamine receptors, lumateperone's activity is unique through its activity at D2 receptors compared to first-generation and other recently introduced second-generation antipsychotics.</p>
        <p>First-generation antipsychotics block D2 receptors both pre-and post-synaptically. Pre-synaptic inhibition of D2 receptors results in positive feedback and a subsequent increase of dopamine in the synaptic cleft. Only post-synaptic receptor blockade is sufficient in this context. Other agents that are second-generation antipsychotics, such as aripiprazole and brexipiprazole, are D2 receptor partial agonists and allow low dopamine D2 receptor neurotransmission. In both cases, there are unwanted increases in dopaminergic activity and, more importantly, the requirement for higher D2 receptor occupancy. Specifically, they are known to require a 60-80% occupancy of D2 receptors to achieve clinical efficacy in reducing symptoms of schizophrenia. This is thought to result in a higher risk of extrapyramidal side effects.<xref ref-type="bibr" rid="article-88058.r13">[13]</xref></p>
        <p>&#x000a0;In contrast, lumateperone's pre-synaptic partial agonist activity prevents positive feedback at D2 receptors while simultaneously blocking dopaminergic neurotransmission at the post-synaptic D2 receptor. This dual action at D2 receptors prevents an increase in dopamine in the synaptic cleft while simultaneously blocking post-synaptic D2 receptors. It is thought that this is responsible for the fact that lumateperone requires D2 receptor occupancy as low as 40%, an uncommon characteristic in antipsychotics.<xref ref-type="bibr" rid="article-88058.r13">[13]</xref> Both reduced receptor occupancy and its dual action at D2 receptors are thought to contribute to lumateperone's low incidence of extrapyramidal side effects, such as tardive dyskinesia and parkinsonian-like effects. Interestingly, lumateperone appears to be regioselective for mesolimbic brain pathways rather than nigrostriatal pathways.<xref ref-type="bibr" rid="article-88058.r13">[13]</xref><xref ref-type="bibr" rid="article-88058.r2">[2]</xref><xref ref-type="bibr" rid="article-88058.r3">[3]</xref>&#x000a0;In addition, post-synaptic antagonism of D2 receptors by lumateperone increases GSK-3 signaling via phosphorylation. GSK3 signaling occurs in D2R-expressing neurons located in the PFC and nucleus accumbens, both of which are implicated in schizophrenia.<xref ref-type="bibr" rid="article-88058.r3">[3]</xref></p>
        <p>Like other second-generation antipsychotics, lumateperone is a 5-HT2A receptor antagonist. The antagonism of 5-HT2A receptors, in addition to the antagonism of D2 receptors, is the defining characteristic of all second-generation antipsychotics. 5-HT2A receptor antagonism, when paired with D2 receptor antagonism, results in a reduced risk of extrapyramidal side effects. The exact mechanism is unknown; however, the 5-HT2A receptor is known to influence dopaminergic activity in the brain.<xref ref-type="bibr" rid="article-88058.r15">[15]</xref></p>
        <p>Importantly, lumateperone exhibits 60x greater affinity for 5-HT2A receptors than D2 receptors. This is thought to be significant in lumateperone's&#x000a0;gradient of clinical effects, which provides lumateperone with a potentially more extensive range of clinical use.<xref ref-type="bibr" rid="article-88058.r3">[3]</xref><xref ref-type="bibr" rid="article-88058.r13">[13]</xref><xref ref-type="bibr" rid="article-88058.r2">[2]</xref>&#x000a0;At low dosages, lumateperone's effects are mainly sedative and anti-aggressive. The ability of lumateperone to exhibit these effects at low dosages may result from a lack of D2 receptor binding and preferential, potent 5HT2A antagonism at low dosages. In contrast, increasing dosages show increasing D2 receptor binding and occupancy in addition to 5HT2A receptor binding, resulting in antipsychotic efficacy.<xref ref-type="bibr" rid="article-88058.r3">[3]</xref>&#x000a0;</p>
        <p>Lumateperone also has other serotonergic modulatory activity acting in addition to being a potent 5-HT2A receptor antagonist. Specifically, it is an inhibitor of the serotonin reuptake transporter, which is the mechanism of action of SSRI antidepressants, resulting in potential antidepressant activity and efficacy against the negative symptoms of schizophrenia (i.e., depression).<xref ref-type="bibr" rid="article-88058.r3">[3]</xref>&#x000a0;This may be an essential factor in lumateperone's&#x000a0;efficacy in both bipolar depression as well as the negative symptoms associated with schizophrenia.</p>
        <p>Lumateperone is unique among other antipsychotics in that it targets the glutamatergic system in the brain. Recently, there has been increasing interest in the role of the glutamatergic system in the neurobiology of schizophrenia. Schizophrenia has been associated with dysregulation of the glutamatergic system in the brain. Unlike dopamine which is restricted to distinct anatomical pathways in the brain, glutamate is the primary excitatory neurotransmitter. As a result, dysregulation of glutamate in the brain may have widespread implications on total brain functioning and is thought to be important to the pathophysiology of schizophrenia.<xref ref-type="bibr" rid="article-88058.r16">[16]</xref></p>
        <p>The NMDA receptors are ionotropic glutamate receptors that are thought to play a role in schizophrenia. Furthermore, it has been proposed that dysregulation of glutamate transmission may be involved in the cognitive deficits associated with negative symptoms of schizophrenia.<xref ref-type="bibr" rid="article-88058.r11">[11]</xref>&#x000a0;It is hypothesized that there is a deficiency of NMDA receptors, a type of ionotropic glutamate receptor present in GABA interneurons in patients with schizophrenia. Lumateperone has been found to target NMDA receptors</p>
        <p>Lumateperone has been found to augment the activities of NMDA and AMPA receptors in the prefrontal cortex. Although the exact mechanism is unknown, it has been found that this is partly through a D1-receptor-mediated mechanism that results in the phosphorylation of GluN2B subunits of NMDA receptors in the mesolimbic pathways of the brain.<xref ref-type="bibr" rid="article-88058.r1">[1]</xref><xref ref-type="bibr" rid="article-88058.r17">[17]</xref>&#x000a0;This correlates with lumateperone's regioselectivity for mesolimbic circuits and lower affinity for nigrostriatal dopamine pathways.<xref ref-type="bibr" rid="article-88058.r13">[13]</xref><xref ref-type="bibr" rid="article-88058.r2">[2]</xref><xref ref-type="bibr" rid="article-88058.r3">[3]</xref> It is thought that this activity may be an important contributor to its effects as an antipsychotic and antidepressant, as NMDA-receptor activity is known to be deficient in schizophrenic patients.<xref ref-type="bibr" rid="article-88058.r3">[3]</xref><xref ref-type="bibr" rid="article-88058.r14">[14]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-88058.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Lumateperone is administered orally, at the FDA-approved dosage of 42 mg in capsule form, preferably at bedtime. Dosages at 120 mg/day have been shown not to produce any statistically significant improvement in efficacy.<xref ref-type="bibr" rid="article-88058.r5">[5]</xref> It shows rapid absorption following oral administration and has a moderate half-life of 13&#x000a0;to 21 hours. T-max occurs in 3&#x000a0;to 4 hours.<xref ref-type="bibr" rid="article-88058.r12">[12]</xref><xref ref-type="bibr" rid="article-88058.r3">[3]</xref>&#x000a0;Lumateperone and its metabolites are entirely excreted in the feces.</p>
      </sec>
      <sec id="article-88058.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects associated with the administration of lumateperone are mild to moderate.<xref ref-type="bibr" rid="article-88058.r8">[8]</xref>&#x000a0;At the FDA-approved dosage of 42mg/day, the most common side effects are somnolence, sedation, fatigue, and constipation.<xref ref-type="bibr" rid="article-88058.r12">[12]</xref>&#x000a0;</p>
        <p>In&#x000a0;a Phase III clinical trial consisting of 148 participants who received the currently FDA-approved dosage of 42 mg, 17.6% experienced somnolence, 12.7% experienced sedation, and&#x000a0; 5.3% experienced fatigue. Overall, 64.7% of this group experienced adverse effects.<xref ref-type="bibr" rid="article-88058.r12">[12]</xref>&#x000a0;No more than 5% of participants in either of the lumateperone groups (n=294) experienced extrapyramidal symptoms. Furthermore, there was no statistically significant change in median weight from the placebo. Metabolic endpoints, including changes in triglycerides, blood glucose, and prolactin levels, also did not change significantly from placebo; this appears to be partially attributable to its lack of affinity to off-target receptors, including histaminergic and muscarinic receptors.<xref ref-type="bibr" rid="article-88058.r12">[12]</xref></p>
        <p>Another clinical trial compared lumateperone to a standard-of-care antipsychotic consisting of 302 patients for six weeks. Those who switched to lumateperone from their current antipsychotics experienced statistically significant improvements in parameters measuring LDL-cholesterol, triglycerides, and prolactin levels.<xref ref-type="bibr" rid="article-88058.r5">[5]</xref><xref ref-type="bibr" rid="article-88058.r8">[8]</xref>&#x000a0;Although there have only been a limited number of clinical trials so far, evidence points to lumateperone having a reduced risk of adverse effects normally associated with second-generation antipsychotics, although long-term studies are underway to determine the&#x000a0;long-term safety and efficacy of lumateperone.<xref ref-type="bibr" rid="article-88058.r6">[6]</xref><xref ref-type="bibr" rid="article-88058.r18">[18]</xref></p>
      </sec>
      <sec id="article-88058.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Lumateperone undergoes metabolism by the cytochrome P450-3A4 isozyme and interacts with medications that are inhibitors and/or inducers of this isozyme. Therefore, the recommendation is to avoid lumateperone in patients taking a CYP3A4 inducer or moderate to potent CYP3A4 inhibitors. Also, lumateperone is likely to interact with alcohol and other sedatives as it produces sedation,&#x000a0;especially at lower dosages.<xref ref-type="bibr" rid="article-88058.r12">[12]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-88058.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The treatment and management of schizophrenia is a multi-dimensional process that involves the coordination and participation of various healthcare practitioners, including psychiatrists, nurses, pharmacists, social workers, and other associated healthcare workers, operating as a coordinated interprofessional team. An alliance between these disciplines is essential to provide the best possible outcome because schizophrenia is a complex disease that necessitates an interprofessional approach to treatment. Because there is no cure for schizophrenia, treatment aims to reduce the symptoms that patients experience. The initial goal is to manage any acute and exacerbated psychotic episodes,&#x000a0;where pharmacological treatment plays an important role.<xref ref-type="bibr" rid="article-88058.r19">[19]</xref>&#x000a0;The interprofessional paradigm is the best way to optimize therapeutic gains when using lumateperone (and other medications) while minimizing potential adverse events. [Level 5]</p>
        <p>Upon proper management of acute symptoms, the other components of schizophrenia, which involve an entire spectrum of psychological, behavioral, and social elements, require attention. Thus, pharmacotherapy is only one aspect of this multi-dimensional paradigm to treat individuals diagnosed with schizophrenia. Treatment of schizophrenia should consider psychological and/or psychosocial therapies and/or other strategies that improve the patient's quality of life, prevent relapse, and manage residual cognitive and behavioral symptoms once the initial symptoms are under control. This approach is especially crucial because pharmacological treatments often cannot address all aspects of the disease.</p>
        <p>Therefore, healthcare professionals such as psychologists, social workers, and therapists play an essential role in the treatment process. Current guidelines by the American Psychiatric Association (APA) indicate the need for individualized pharmacological approaches based on the patient's personal preference, clinical response, and adverse effects.<xref ref-type="bibr" rid="article-88058.r19">[19]</xref>&#x000a0;The patient and the interprofessional team must&#x000a0;work collaboratively in the decision-making process. Without proper management, schizophrenia can be a debilitating and sometimes life-threatening condition in which the patient may potentially harm themselves or others. Therefore, healthcare team members must discuss strategies and communicate effectively to provide the best outcome possible.&#x000a0;</p>
      </sec>
      <sec id="article-88058.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=88058&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=88058">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/88058/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=88058">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-88058.s9">
        <title>References</title>
        <ref id="article-88058.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maini</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hollier</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bollich</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>John LaForge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Edinoff</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia.</article-title>
            <source>Health Psychol Res</source>
            <year>2021</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>24932</fpage>
            <pub-id pub-id-type="pmid">34746489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kantrowitz</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>The Potential Role of Lumateperone-Something Borrowed? Something New?</article-title>
            <source>JAMA Psychiatry</source>
            <year>2020</year>
            <month>Apr</month>
            <day>01</day>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>343</fpage>
            <page-range>343-344</page-range>
            <pub-id pub-id-type="pmid">31913409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vyas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bra&#x00161;i&#x00107;</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>An evaluation of lumateperone tosylate for the treatment of schizophrenia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-145</page-range>
            <pub-id pub-id-type="pmid">31790322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blair</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Lumateperone: First Approval.</article-title>
            <source>Drugs</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>417</fpage>
            <page-range>417-423</page-range>
            <pub-id pub-id-type="pmid">32060882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corponi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bitter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vieta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pallanti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Serretti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>971</fpage>
            <page-range>971-985</page-range>
            <pub-id pub-id-type="pmid">31255396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calsolaro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Antognoli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Okoye</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Monzani</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer's Disease.</article-title>
            <source>Front Pharmacol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>1465</fpage>
            <pub-id pub-id-type="pmid">31920655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snyder</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Vanover</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fienberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mates</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia.</article-title>
            <source>Adv Pharmacol</source>
            <year>2021</year>
            <volume>90</volume>
            <fpage>253</fpage>
            <page-range>253-276</page-range>
            <pub-id pub-id-type="pmid">33706936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krogmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>von Hardenberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>B&#x000f6;deker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>N&#x000f6;hles</surname>
                <given-names>VB</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
            </person-group>
            <article-title>Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities.</article-title>
            <source>CNS Spectr</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>S1</issue>
            <fpage>38</fpage>
            <page-range>38-69</page-range>
            <pub-id pub-id-type="pmid">31482779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Traversi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Janiri</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders.</article-title>
            <source>CNS Neurol Disord Drug Targets</source>
            <year>2020</year>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>243</fpage>
            <page-range>243-247</page-range>
            <pub-id pub-id-type="pmid">32479249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenwood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Acharya</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Marcellus</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rey</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Lumateperone: A Novel Antipsychotic for Schizophrenia.</article-title>
            <source>Ann Pharmacother</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>98</fpage>
            <page-range>98-104</page-range>
            <pub-id pub-id-type="pmid">32590907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Titulaer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Radhe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Danielsson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dutheil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Jardemark</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Ericson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Konradsson-Geuken</surname>
                <given-names>&#x000c5;</given-names>
              </name>
            </person-group>
            <article-title>Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D<sub>1</sub> receptor dependent mechanism.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>62</volume>
            <fpage>22</fpage>
            <page-range>22-35</page-range>
            <pub-id pub-id-type="pmid">35878581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Weingart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saillard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Gorman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tamminga</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Mates</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vanover</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.</article-title>
            <source>JAMA Psychiatry</source>
            <year>2020</year>
            <month>Apr</month>
            <day>01</day>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>349</fpage>
            <page-range>349-358</page-range>
            <pub-id pub-id-type="pmid">31913424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanover</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bra&#x00161;i&#x00107;</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Gapasin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saillard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weingart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Litman</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Mates</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Dopamine D<sub>2</sub> receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>598</fpage>
            <page-range>598-605</page-range>
            <pub-id pub-id-type="pmid">30449883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kuhad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuhad</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Lumateperone: a new treatment approach for neuropsychiatric disorders.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>12</issue>
            <fpage>713</fpage>
            <page-range>713-719</page-range>
            <pub-id pub-id-type="pmid">30596390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aringhieri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kolachalam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verdesca</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McCormick</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Corsini</surname>
                <given-names>GU</given-names>
              </name>
              <name>
                <surname>Maggio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Scarselli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences.</article-title>
            <source>Pharmacol Ther</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>192</volume>
            <fpage>20</fpage>
            <page-range>20-41</page-range>
            <pub-id pub-id-type="pmid">29953902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCutcheon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Krystal</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Howes</surname>
                <given-names>OD</given-names>
              </name>
            </person-group>
            <article-title>Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.</article-title>
            <source>World Psychiatry</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-33</page-range>
            <pub-id pub-id-type="pmid">31922684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edinoff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>deBoisblanc</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Feltner</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Norder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tzoneva</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Viswanath</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Urits</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Lumateperone for the Treatment of Schizophrenia.</article-title>
            <source>Psychopharmacol Bull</source>
            <year>2020</year>
            <month>Sep</month>
            <day>14</day>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>32</fpage>
            <page-range>32-59</page-range>
            <pub-id pub-id-type="pmid">33012872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snyder</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Vanover</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>O'Callaghan</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Tomesch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hendrick</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Nestler</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Wennogle</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Mates</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission.</article-title>
            <source>Psychopharmacology (Berl)</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>232</volume>
            <issue>3</issue>
            <fpage>605</fpage>
            <page-range>605-21</page-range>
            <pub-id pub-id-type="pmid">25120104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88058.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maroney</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>An update on current treatment strategies and emerging agents for the management of schizophrenia.</article-title>
            <source>Am J Manag Care</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3 Suppl</issue>
            <fpage>S55</fpage>
            <page-range>S55-S61</page-range>
            <pub-id pub-id-type="pmid">32282175</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
